After almost halving from last year's peak, WTI looks to be breaking out to the upside, and USO is well-placed to benefit. Read more to see my thoughts on the ETF.Read full newsRead More
SBC has been a focus of many lately, given the egregious numbers posted QoQ in financial results. Check out the worst SBC offenders and a few of the best.Read full newsRead More
Amazon is quietly transforming into a service-based company as advertising, AWS cloud services, Prime, and others grow. See why I rate AMZN stock a buy.Read full newsRead More
The United States of America has been the incubator of wealth and success. I don't bet against it - I bet on it. Read more to see our income picks.Read full newsRead More
Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage? Importance of patents and cash in the industry.Read full newsRead More
Cliq Digital is a challenger on the German streaming market but is rapidly gaining market share. See why I'm on the sidelines for now on the stock.Read full newsRead More
We believe peak inflation is behind us, and our projections for inflation over the course of 2023 and 2024 changed little upon the release of December CPI.Read full newsRead More
Top-ten 2023 inflation-busting dividend stocks boasted net gains from 16.64% to 39% per YCharts forward-looking data 1/12/23.Read full newsRead More
Affirm's exclusive BNPL partnership with Amazon is ending soon by January 2023. Click here to read our analysis of the impact on AFRM stock.Read full newsRead More
USA yields over 9%, ASG yields over 8%. Click here to read the full investment analysis and comparison of these two closed-end funds.Read full newsRead More
We expect 2023 to be different-a year of transition. Inflation will still dominate headlines, likely for months to come.Read full newsRead More
Disinflation dominated the discussion after the closely-watched CPI-ex-Shelter Index was negative for the fifth month in the past six.Read full newsRead More
There is no further clarity on the delay of the NDA from Amicus Therapeutics for AT-GAA in Pompe disease. Click here to see our take on FOLD stock.Read full newsRead More
ECC offers more than 15% yield on its commons through investments in risky but high-return collateralized loan obligations. See why I'm neutral on the fund.Read full newsRead More
Vaxcyte has had a massive rally in its shares since late October. What next for this vaccine concern? Find out what investors need to know about PCVX stock.Read full newsRead More
We take a look at the action in preferreds and baby bonds through first week of January and highlight some key themes. Click here to read more about them.Read full newsRead More
Old Republic has a long track record of shareholder returns. See why investors may want to consider a position in ORI at its current below average valuation.Read full newsRead More
BlackRock delivered a robust Q4 earnings release. Read more to see why the reward/risk doesn't look attractive in BLK stock.Read full newsRead More
Intel officially launched its Sapphire Rapid data center processors last week. Click here for a full investment analysis of INTC stock.Read full newsRead More
Over the long term, I think Sleep Number Corporation could be a solid holding. But see why I see taking a position in SNBR stock as far riskier now.Read full newsRead More